within Pharmacolibrary.Drugs.ATC.A;

model A04AA04_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.00018333333333333334,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600,            
    Vdp             = 0.00275,
    k12             = 5.4,
    k21             = 5.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AA04_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dolasetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting associated with chemotherapy, radiation, and surgery. It is currently approved for medical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Dimmitt, DC, et al., &amp; Weir, SJ (1998). Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment. <i>Journal of clinical pharmacology</i> 38(9) 798–806. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9753207/\">https://pubmed.ncbi.nlm.nih.gov/9753207</a></p></li><li><p>Stubbs, K, et al., &amp; Hahne, WF (1997). Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction. <i>Journal of clinical pharmacology</i> 37(10) 926–936. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1997.tb04267.x\">10.1002/j.1552-4604.1997.tb04267.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9505984/\">https://pubmed.ncbi.nlm.nih.gov/9505984</a></p></li><li><p>Dimmitt, DC, et al., &amp; Weir, SJ (1999). Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. <i>Biopharmaceutics &amp; drug disposition</i> 20(1) 29–39. DOI:<a href=\"https://doi.org/10.1002/(sici)1099-081x(199901)20:1&lt;29::aid-bdd151&gt;3.0.co;2-s\">10.1002/(sici)1099-081x(199901)20:1&lt;29::aid-bdd151&gt;3.0.co;2-s</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10086835/\">https://pubmed.ncbi.nlm.nih.gov/10086835</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AA04_1;
